Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT03529539 No longer available - Clinical trials for Neuroendocrine Tumor

Expanded Access Non Emergency Use Single Subject Study Protocol for Metastatic Neuroendocrine Tumor of the Pancreas

PSV2
Start date: n/a
Phase:
Study type: Expanded Access

A single patient protocol for intermediate grade nonfunctional metastatic pancreatic neuroendocrine disease that has exhausted all standard therapy having progressed on chemotherapy and immunotherapy.

NCT ID: NCT03511768 Recruiting - Clinical trials for Neuroendocrine Neoplasm

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Start date: January 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide(18F-AlF-NOTA-octreotide ) positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

NCT ID: NCT03498040 Not yet recruiting - Clinical trials for Carcinoid Heart Disease

Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors

CRUSOE-NETs
Start date: April 2018
Phase:
Study type: Observational

Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of disease remain unclear. This observational multicenter cohort study is designed to study the occurrence of Carcinoid Heart Disease in patients with differentiated carcinoid tumors, to describe numerous factors influencing the occurrence, severity, progression and long-term survival of patients with Carcinoid Heart Disease. Basic informations and detailed diagnosis informations (oncological and cardiac parameters), are collected by professional doctors. Clinical outcomes (onset of Carcinoid Heart Disease, cardiac surgery, related death) will be followed up every year or every six/three months if clinically indicated.

NCT ID: NCT03478358 Recruiting - Clinical trials for Neuroendocrine Tumors

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Start date: April 30, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, non-controlled, non-randomized study to investigate the long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluate response to 177Lu-DOTAEB-TATE in patients with advanced metastatic neuroendocrine tumors. Different groups with doses of 0.37GBq-0.74GBq (10-20 mCi) and 1.85GBq (50 mCi)of 177Lu-DOTA-EB-TATE,3.7GBq (100 mCi)of 177Lu-DOTA-TATE will be injected intravenously. All patients will undergo 68Ga-DOTATATE PET/CT scans before and after the treatment.

NCT ID: NCT03466216 Recruiting - Clinical trials for Neuroendocrine Tumor

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

Start date: February 5, 2018
Phase: Phase 1
Study type: Interventional

AlphaMedix™ (²¹²Pb-DOTAMTATE) is a radiotherapeutic drug indicated in subjects with unresectable, metastatic somatostatin receptor (SSTR) positive neuroendocrine tumors (NETs). Because 212Pb is an in vivo generator of alpha particles, it is particularly suitable for SSTR therapy applications. This drug addresses an unmet need in the field of peptide receptor radionuclide therapy (PRRT) for NETs. Substitution of an alpha emitter (²¹²Pb) for the beta emitters currently being used (i.e., 177Lu or 90Y) will provide significantly higher Linear Energy Transfer (LET) and a shorter path length. Higher LET particles should cause more tumor cell death. Shorter path length should result in less collateral damage of the normal tissue and therefore less side effects for subjects receiving the drug.

NCT ID: NCT03457948 Not yet recruiting - Clinical trials for Neuroendocrine Neoplasm

Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases

Start date: March 31, 2018
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well pembrolizumab and liver-directed therapy works in treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Liver-directed therapies such as radiofrequency ablation, transarterial embolization, yttrium-90 microsphere radioembolization, and cryoablation may help to shrink tumors that are not being directly targeted. Giving pembrolizumab and liver-directed therapy may work better in treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver.

NCT ID: NCT03457844 Recruiting - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumor G3

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Start date: January 30, 2018
Phase: Phase 2
Study type: Interventional

To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.

NCT ID: NCT03454763 Recruiting - Clinical trials for Neuroendocrine Tumors

Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors

LUTHREE
Start date: May 26, 2016
Phase: Phase 2
Study type: Interventional

Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate

NCT ID: NCT03453489 Not yet recruiting - Carcinoid Syndrome Clinical Trials

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm

Start date: April 30, 2018
Phase: Phase 2
Study type: Interventional

This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying the changes within the tumor cells via AMT-PET may help doctors better understand how tumors respond to treatment with telotristat etiprate.

NCT ID: NCT03452774 Recruiting - Breast Cancer Clinical Trials

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Start date: January 1, 2018
Phase: N/A
Study type: Observational [Patient Registry]

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.